LTR PharmaASX:LTP -4.27%15 Altman Z-Score is 87.07 as of Jun. 26, 2026, which is 94% above its 10-year median of 44.87. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 934 Biotechnology companies, LTR Pharma ranks better than 98.5% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 91.74 is strong.
LTR Pharma has a Altman Z-Score of 87.07, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for LTR Pharma's Altman Z-Score or its related term are showing as below:
ASX:LTP'
s Altman Z-Score Range Over the Past 10 Years
Min: 44.87 Med: 44.87 Max: 91.74
Current: 91.74
During the past 5 years, LTR Pharma's highest Altman Z-Score was 91.74. The lowest was 44.87. And the median was 44.87.
LTR Pharma (ASX:LTP) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
LTR Pharma Altman Z-Score Related Terms
LTR Pharma Altman Z-Score Historical Data
* Premium members only.
The historical data trend for LTR Pharma's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:LTP vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, LTR Pharma's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LTR Pharma Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LTR Pharma's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where LTR Pharma's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
LTR Pharma's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.974
+
1.4
*
-0.4679
+
3.3
*
-0.1737
+
0.6
*
145.214
+
1.0
*
0.0045
=
87.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
LTR Pharma (ASX:LTP) has a Altman Z-Score of 87.07 as of Jun. 26, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on LTR Pharma and its competitors. This is 94% above median its historical median of 44.87. Over the past decade, LTR Pharma's Altman Z-Score has ranged from 44.87 to 91.74. According to the industry distribution chart, LTR Pharma ranks #14 out of 934 companies in the Biotechnology industry, placing it in the top 1.5%.
Is LTR Pharma's Altman Z-Score too high?
LTR Pharma's current Altman Z-Score of 87.07 is 94% above median its 10-year median of 44.87. Over the past 10 years, this metric has ranged from a low of 44.87 to a high of 91.74. The Biotechnology industry median Altman Z-Score is 2.63. LTR Pharma's value of 87.07 is 3217% above this industry median. Based on the distribution chart, LTR Pharma ranks #14 out of 934 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #14 out of 934 companies for Altman Z-Score. This places LTR Pharma in the top 2% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.63. LTR Pharma's value of 87.07 is 3217% above this benchmark. Historically, LTR Pharma's own Altman Z-Score has ranged from 44.87 to 91.74 over the past decade. While the company's 10-year median is 44.87 vs. the industry median of 2.63, LTR Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.63, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LTR Pharma's current Altman Z-Score of 87.07 is 3217% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on LTR Pharma and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LTR Pharma's current Altman Z-Score is 87.07, which is 94% above median its own 10-year median of 44.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Altman Z-Score of 87.07. The current Altman Z-Score is 87.07, which is 94% above median its 10-year median of 44.87 and 3217% above the Biotechnology industry median of 2.63. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Altman Z-Score is 87.07 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score
Get the complete analysis for ASX:LTP
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LTP has been successfully added to your 